Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. - Wikidata - awgldk - TriplyDB

Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy.

Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy.

http://www.wikidata.org/entity/Q35575973

about

Syntaxin 4 is required for acid sphingomyelinase activity and apoptotic function Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts Mitochondrial biogenesis: regulation by endogenous gases during inflammation and organ stress Nutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the Conjecture Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy Glucocorticoid-induced leucine zipper (GILZ) and long GILZ inhibit myogenic differentiation and mediate anti-myogenic effects of glucocorticoids Amelioration of Duchenne muscular dystrophy in mdx mice by elimination of matrix-associated fibrin-driven inflammation coupled to the αMβ2 leukocyte integrin receptor Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice Attempting to Compensate for Reduced Neuronal Nitric Oxide Synthase Protein with Nitrate Supplementation Cannot Overcome Metabolic Dysfunction but Rather Has Detrimental Effects in Dystrophin-Deficient mdx Muscle.Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers.Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy Golgi and sarcolemmal neuronal NOS differentially regulate contraction-induced fatigue and vasoconstriction in exercising mouse skeletal muscle Sildenafil increases muscle protein synthesis and reduces muscle fatigue.Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures.Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans.Deficient nitric oxide signalling impairs skeletal muscle growth and performance: involvement of mitochondrial dysregulation.Loss of nNOS inhibits compensatory muscle hypertrophy and exacerbates inflammation and eccentric contraction-induced damage in mdx mice.Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice Stem cell transplantation for treating Duchenne muscular dystrophy: A Web of Science-based literature analysis Nitrosative stress elicited by nNOSµ delocalization inhibits muscle force in dystrophin-null mice A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy.Modulation of Acid Sphingomyelinase in Melanoma Reprogrammes the Tumour Immune Microenvironment Regenerative potential of human muscle stem cells in chronic inflammation.Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy.Nitric oxide sustains long-term skeletal muscle regeneration by regulating fate of satellite cells via signaling pathways requiring Vangl2 and cyclic GMP.uPA deficiency exacerbates muscular dystrophy in MDX mice.Nitric Oxide Donor Molsidomine Positively Modulates Myogenic Differentiation of Embryonic Endothelial Progenitors.Co-administration of aspirin and allogeneic adipose-derived stromal cells attenuates bone loss in ovariectomized rats through the anti-inflammatory and chemotactic abilities of aspirin Emerging drugs for Duchenne muscular dystrophy Nitric oxide in skeletal muscle: role on mitochondrial biogenesis and function.Requirement of inducible nitric oxide synthase for skeletal muscle regeneration after acute damage.Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat Design of aging intervention studies: the NIA interventions testing program.HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment.Regenerative pharmacology in the treatment of genetic diseases: the paradigm of muscular dystrophy Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model.Mesenchymal stem cells: emerging therapy for Duchenne muscular dystrophy Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Inflammation and Fibrosis of Skeletal Muscles Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy.

P2860

Q24303872-56A5A72B-B5D1-48E8-8CE1-E5315F60BD14 Q24629251-184C8FC9-0BF9-4D29-8A35-E1B05DB7F3A6 Q27025057-899A180A-6608-4420-87C1-DB0924A70A72 Q28072269-D322B44B-8B4B-4095-8A2E-2E0A0DC59675 Q28484851-8548F8DE-014F-46A9-907E-6C161E7D1631 Q28509978-F6AA66D2-447F-4024-A8D7-2B9A98A15197 Q30512264-3B92B504-908F-4CCE-90EC-C53FAA38BCA8 Q33375717-C3732497-8BC0-4649-BB41-913430C87CB1 Q33586004-B00D8E54-7C57-4156-8FD6-83410CF94A81 Q33599468-7E228387-7103-4CD2-940D-2BBE1216BCBD Q33649312-5474CC24-28C1-4A61-A979-8066E0EA6F1F Q33685640-0AD324FA-F425-4037-9AD8-46B5F05F824F Q33827719-C39052C6-B081-4404-916C-F148F711C450 Q33975979-760958FD-8C9B-406D-A714-09A0FBC09AF0 Q34124872-D1D3042F-EA53-4C43-9FE8-8DBF7896D332 Q34748781-DE00A66E-9F75-46A1-B323-7B1E3178F1CC Q34764061-F74A3DBB-94DB-4507-9EDA-8318CEE5816E Q34796688-C031D724-24E6-416E-9DA5-E7AE7827F63B Q34997665-D4DB8C0E-2DF9-43D1-9DEE-6653C3ACC6DE Q35027817-AB84064C-437F-4646-94DB-A7B4BB61C37E Q35100498-70607946-7735-40D1-8A32-2290D67A3547 Q35697896-6E4F9F76-3D0D-4AB8-A82D-0A353C520DB2 Q35907825-35F61777-35B7-4E6A-8AB8-7DC35F170CA3 Q35986842-0D6B82D9-F9E7-44F9-A6CD-83412414D2DD Q36043923-D1B89AA7-F8E1-4EB5-9AC4-110DE5E221A4 Q36119288-F39C763A-D0D8-482D-ADA0-9C919C0C0A98 Q36168025-1077FB71-D978-4EC9-B2FE-26268E931711 Q36171968-180EAF74-1F1A-4C67-9BAD-6AE6E8C9C252 Q36363716-16C983E6-42AE-4248-8CC7-840976A1946D Q36538574-9B4A0771-083E-4ADB-B1CA-4C081429CA91 Q36593335-248D13C4-F6CF-46BB-BA78-3BECE7F8274F Q36841572-9F81D039-CA8C-4155-AFEA-2BCA86B1B056 Q36885666-3D4BBC1C-960B-44C8-BA6A-447288F13FD4 Q36979385-9CF1514C-575D-4E4B-ADA0-E3AEBB522737 Q37039472-878095FA-D372-4DBB-9161-CA6E56B84B6C Q37274303-B0A83029-1EEB-4D84-AA8C-54E6EE94D642 Q37494390-6FA15529-56B8-4FB3-B4DE-EFEB78726A70 Q37560090-7253F623-49DA-43C8-B486-B8E363A955C2 Q37589790-E17D40FC-F8D9-4222-9C77-419820A32BE1 Q37604365-A5760878-64CD-4D53-972F-E631342438B5

P2860

Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy.

http://www.wikidata.org/entity/Q35575973

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Nitric oxide release combined ...... nd enhances stem cell therapy.

@ast

Nitric oxide release combined ...... nd enhances stem cell therapy.

@en

type

label

Nitric oxide release combined ...... nd enhances stem cell therapy.

@ast

Nitric oxide release combined ...... nd enhances stem cell therapy.

@en

prefLabel

Nitric oxide release combined ...... nd enhances stem cell therapy.

@ast

Nitric oxide release combined ...... nd enhances stem cell therapy.

@en

P1433

Q35575973-2C1E7ADE-C3B0-4DAF-955B-F06D54929218

P1476

Q35575973-35139FD2-BA18-4E32-90C0-061B0A3DFD8B

P2093

Q35575973-52FEB2AF-FA7D-4F7B-B305-819C22A8502D

Q35575973-58584A5B-E36F-403A-8C8E-10E4C2F83413

Q35575973-5C9F9BCF-3434-4DCD-8FB9-D06D5771D5CA

Q35575973-623B0D64-42AA-4848-8255-00A6C8B9F898

Q35575973-69D41F40-CADB-4E7E-BAF4-E0C085114343

Q35575973-8443C409-2CDF-40DA-ABA0-C65FED7071DC

Q35575973-D920AD1E-6543-48E5-B149-4741DA3F63FE

P2860

Q35575973-0004E8CB-1B29-447F-A822-F74C7A11C306

Q35575973-0884BDE4-9130-4E9D-A2FA-C3CB17B2DA78

Q35575973-1B5A15E0-8422-4D23-8D24-1E187E307314

Q35575973-23C6B3D1-D021-4FB4-9714-EC2CB62FD447

Q35575973-2D0A2CE0-C040-47D4-AC3B-C838A5FAA849

Q35575973-2E55E4E8-7CE3-4730-BF28-40207665058F

Q35575973-33BAFDA8-D1C3-4685-9E89-E8504A12FD17

Q35575973-343C0F46-76A0-4046-90C0-74FF1D46B766

Q35575973-4FE6E53F-90D2-4B01-9303-07987DAE341D

Q35575973-593E1C8C-0229-46C2-88D9-A3F84479A079

P304

Q35575973-93F10B45-9FAF-42F1-9001-9E9599547580

P31

Q35575973-3554498C-3281-4527-9832-F479222E897C

P356

Q35575973-7EF15539-BD17-4F50-80E5-F32640288E92

P407

Q35575973-5FB52339-B02D-4AD4-98DD-F8829016263E

P433

Q35575973-92A33CAE-859C-4D59-A139-3590773B6804

P478

Q35575973-9A658C51-7F73-40C5-99E9-8EA388FBC521

P50

Q35575973-0B1B56B4-C608-400B-866F-8B2FE860B400

Q35575973-144F1580-DC47-4D39-974C-21047C8C3B22

Q35575973-221AC2CF-A1EC-4E29-89CA-36C8AFED69C4

Q35575973-3A28FDF4-B641-43EC-B307-930C4944A594

Q35575973-5697DF74-9FE9-4F7D-949C-135E42728169

Q35575973-7B4BBEF3-E47B-4D65-9ECA-CEE06FA1C6C8

P577

Q35575973-D0EE6FE3-AF79-4CDC-B569-00F83A731BAA

P5875

Q35575973-3511BEDB-7F94-460C-A944-1FF63FF61F2E

P698

Q35575973-3B8DBBB4-0340-4BAC-93F6-F218F897A79E

P932

Q35575973-E33EE07D-6C17-45D5-8DC8-8AF5B9E79DF8

P356

PNAS.0608277104

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Nitric oxide release combined ...... nd enhances stem cell therapy.

@en

P2093

Angela Monopoli

http://www.w3.org/2001/XMLSchema#string

Anna Innocenzi

http://www.w3.org/2001/XMLSchema#string

Diego Covarello

http://www.w3.org/2001/XMLSchema#string

Ennio Ongini

http://www.w3.org/2001/XMLSchema#string

Francesca Sanvito

http://www.w3.org/2001/XMLSchema#string

Giulio Cossu

http://www.w3.org/2001/XMLSchema#string

Roberto Bottinelli

http://www.w3.org/2001/XMLSchema#string

P2860

Glucocorticoid corticosteroids for Duchenne muscular dystrophy

Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat

Release of hepatocyte growth factor from mechanically stretched skeletal muscle satellite cells and role of pH and nitric oxide.

Cell Therapy of -Sarcoglycan Null Dystrophic Mice Through Intra-Arterial Delivery of Mesoangioblasts

Experimental and therapeutic approaches to muscular dystrophies.

Physiology of nitric oxide in skeletal muscle.

The new frontier in muscular dystrophy research: booster genes.

Satellite cell depletion in degenerative skeletal muscle.

Nitroflurbiprofen (NicOx).

New therapies for muscular dystrophy: cautious optimism.

P304

264-269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0608277104

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

Silvia Brunelli

Cristiana Perrotta

Giuseppe D'Antona

Emilio Clementi

Beatriz G. Gálvez

P577

2006-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6617175

http://www.w3.org/2001/XMLSchema#string

P698

17182743

http://www.w3.org/2001/XMLSchema#string

P932

1765447

http://www.w3.org/2001/XMLSchema#string